HOME >
IBL News >
Plasma ANGPTL8: Usefulness to predict residual risk of secondary cardiovascular event in patients with chronic coronary artery disease on pitavastatin therapy.

IBL News

Product News

Product News2023/09/19: Plasma ANGPTL8: Usefulness to predict residual risk of secondary cardiovascular event in patients with chronic coronary artery disease on pitavastatin therapy.

Any IBL product introduced in this IBL news is applicable for research use only and it cannot be used for diagnosis or medical purpose.

Dr. Jun Morinaga, MD, PhD, and Prof. Yuichi Oike, MD, PhD, Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, et al. used samples from randomized control trial known as REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) targeting Japanese patients, and conducted a case-cohort designed biomarker study to investigate the ability of plasma ANGPTL8 to predict secondary cardiovascular event.

Morinaga J et al. Plasma ANGPTL8 Levels and Risk for Secondary Cardiovascular Events in Japanese Patients With Stable Coronary Artery Disease Receiving Statin Therapy. Arterioscler Thromb Vasc Biol. 2023 Aug;43(8):1549-1559.

（Background）
Residual risk assessment of statin treatment has become important for improving health of patients with stable coronary artery disease. Under these circumstances, progress is being made in the development of biopharmaceuticals such as antibody drugs and nucleic acid drugs targeting ANGPTL3, which is thought to be activated by ANGPTL8 to inhibit LPL activity and subsequently worsen lipid profiles in human.

In this case-cohort study, they analysed samples of 2,250 stable CAD patients treated with low-dose (1 mg/day) or high-dose (4 mg/day) pitavastatin selected from 12,413 patients in the REAL-CAD main study. They reported and concluded the following regarding the relationship between ANGPTL8 and the risk of secondary cardiovascular events.

■	Relative changes in ANGPTL8 levels were significantly associated with increased risk of secondary CV events in all patients (high-dose group + low-dose group).
■	In subgroup analysis, there were relatively strong relationships between increased circulating ANGPTL8 levels and secondary cardiovascular events in the high-dose pitavastatin group.
■	Monitoring ANGPTL8 levels over time might be useful to assess the residual risk of secondary cardiovascular events in patients with cardiovascular disease receiving statin therapy.